Pravastatin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Pravastatin
- Pravastatin: From Hyperlipidaemia and Atherosclerosis to Homozygous Familial Hypercholesterolaemia
Pravastatin: From Hyperlipidaemia and Atherosclerosis to Homozygous Familial Hypercholesterolaemia
One-Sentence Summary
Pravastatin is a statin (HMG-CoA reductase inhibitor) originally used for hyperlipidaemia, atherosclerosis and stroke-related conditions. The TxGNN model predicts it may be effective for homozygous familial hypercholesterolaemia, but the data compiled for this report contain no clinical trial testing pravastatin in this condition and only general reviews and guideline literature, so the supporting evidence is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertriglyceridaemia, stroke, cerebrovascular disorder, cerebral infarction, atherosclerosis, familial combined hyperlipidaemia, hyperlipoproteinaemia (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Homozygous familial hypercholesterolaemia |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold (as a research question) |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Based on general knowledge, pravastatin inhibits HMG-CoA reductase, reduces cholesterol synthesis in the liver and upregulates hepatic LDL receptors, which lowers LDL cholesterol.
In homozygous familial hypercholesterolaemia, LDL receptor function is absent or severely reduced. Statin efficacy therefore depends on any residual receptor activity and is expected to be modest compared with PCSK9 inhibitors or other add-on agents. One of the reviews notes that statins are "not very effective" in this form of the disease. Pravastatin is already used in children with the heterozygous form, which is related but a distinct population. The prediction is biologically plausible but is unlikely to represent a strong benefit.
A further observation: other predictions for this drug are better supported. Familial hypercholesterolaemia and autosomal dominant hypercholesterolaemia (both essentially the heterozygous form) reached evidence level L2 with a "Proceed with Guardrails" recommendation. They are close to an established, guideline-supported use rather than true repurposing. HIV-associated dyslipidaemia (evidence level L3) also has a considerable body of trials, although it concerns managing lipids and cardiovascular risk, not treating HIV itself.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03510715 | Phase 3 | Completed | 18 | Open-label study of alirocumab (not pravastatin) in children and adolescents aged 8–17 with homozygous FH; pravastatin is at most background therapy, so it is not direct evidence |
No trial of pravastatin itself in homozygous familial hypercholesterolaemia was identified.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28685504 | 2017 | Cochrane review | Cochrane Database Syst Rev | Statins for children with familial hypercholesterolaemia (mainly the heterozygous form) |
| 31696945 | 2019 | Cochrane review | Cochrane Database Syst Rev | Updated review of statins in children with familial hypercholesterolaemia |
| 28437620 | 2017 | Guideline | Endocr Pract | AACE/ACE guidelines for dyslipidaemia management and cardiovascular prevention |
| 15532136 | 2004 | Commentary | Prescrire Int | Simvastatin and pravastatin are reference statins for heterozygous FH; statins are not very effective in homozygous FH |
| 12269853 | 2002 | Review | Drugs | Rosuvastatin review; superior to pravastatin and others in lipid improvement |
| 15531000 | 2004 | Review | Clin Ther | Rosuvastatin is indicated in homozygous FH |
| 14727947 | 2003 | Review | Am J Cardiovasc Drugs | Ezetimibe, a cholesterol absorption inhibitor |
| 14647533 | 2003 | Review | Cardiovasc Drug Rev | Ezetimibe as a first-in-class agent |
Most of these publications concern other drugs or the heterozygous form; none is a pravastatin trial in homozygous FH.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12671P | APO-PRAVASTATIN TABLET 10 mg | Tablet | Not stated in registration record |
| SIN12670P | APO-PRAVASTATIN TABLET 20 mg | Tablet | Not stated in registration record |
| SIN14508P | PRAVAFEN HARD CAPSULES 40mg/160mg | Capsule | Not stated in registration record |
All three are valid single-ingredient registrations (Pravafen is a pravastatin/fenofibrate product by its strengths, though the record lists it as single).
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text, so they should be verified against the package insert): liver disease, kidney disease, myopathy and other muscle diseases, rhabdomyolysis, gallbladder disease, thrombocytopenia and thrombocytopenic purpura, peptic ulcer disease, gout, anaemia, hypercalcaemia, hyperparathyroidism, haemophilia, sarcoidosis, substance abuse/dependence, and others.
- Drug interactions (100 recorded; moderate-level ones listed): metronidazole, clarithromycin, eluxadoline, naltrexone, pectin, rosuvastatin, simvastatin, tinidazole. Combining statins (e.g. with rosuvastatin or simvastatin) is generally not advised. In HIV patients, interactions with protease inhibitors (e.g. darunavir/ritonavir) can raise pravastatin exposure.
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there is no pravastatin-specific trial in homozygous familial hypercholesterolaemia. Because LDL receptor function is severely impaired, benefit is expected to be limited, and other agents (PCSK9 inhibitors and similar) are better supported. By contrast, pravastatin in heterozygous FH (L2) is already a standard use and could be prioritised instead.
To proceed, the following is needed:
- Pravastatin-specific clinical data (even small studies) in homozygous FH, including response by residual LDL receptor activity
- Detailed mechanism of action data
- Package insert warnings and contraindications from the HSA, with official approved indications for the three Singapore registrations
- Comparison against, or add-on assessment with, PCSK9 inhibitors and other agents used in homozygous FH
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.